Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Department of Obstetrics and Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
J Zhejiang Univ Sci B. 2022 Feb 15;23(2):158-163. doi: 10.1631/jzus.B2100502.
At present, endometriosis remains a worldwide health burden, with the main symptoms of dysmenorrhea, chronic pelvic pain, and infertility, markedly reducing the quality of life (de Ziegler et al., 2010). Although there is no proof that the disease is associated with high mortality, this disorder can significantly contribute to the deterioration of women's general well-being (McPeak et al., 2018). The main current treatment for endometriosis is surgery to remove endometriotic lesions; however, the recurrence rate following surgical treatment is as high as 21.5% at two years and 40.0%-50.0% at five years post-surgery (Koga et al., 2015). To prevent recurrence, adjuvant treatment with drugs after surgery is recommended to prolong relapse-free intervals. However, it is inconvenient for patients to continuously use such medications in terms of adverse effects and cost (Turk, 2002).
目前,子宫内膜异位症仍是全球范围内的健康负担,主要症状为痛经、慢性盆腔痛和不孕,显著降低了生活质量(de Ziegler 等人,2010 年)。尽管没有证据表明该疾病与高死亡率有关,但这种疾病会显著导致女性整体健康状况恶化(McPeak 等人,2018 年)。子宫内膜异位症的主要当前治疗方法是手术切除子宫内膜异位病灶;然而,手术后两年的复发率高达 21.5%,五年后复发率高达 40.0%至 50.0%(Koga 等人,2015 年)。为了预防复发,建议手术后用药物进行辅助治疗以延长无复发间隔。然而,由于不良反应和成本问题,患者连续使用此类药物并不方便(Turk,2002 年)。